|
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Number of employees : 2 700 people.
|
|
| 2020 | 2021 | Delta | mRNA Medicines | 803.40 | 100% | 18 471.00 | 100% | +2199.12% |
USD in Million |
|
|
| 2020 | 2021 | Delta | Europe | - | - | 6 846.00 | 37.1% | - |
United States | 764.53 | 95.2% | 6 177.00 | 33.4% | +707.95% |
Rest of World | 38.87 | 4.8% | 5 448.00 | 29.5% | +13917.39% |
USD in Million |
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
Stock A |
1 |
397,759,517 |
360,280,736 |
90.6% |
0 |
0.0% |
90.6% |
|
|
Name | Equities | % | Baillie Gifford & Co. | 45,629,226 |
11.5% | The Vanguard Group, Inc. | 25,612,184 |
6.44% | Stéphane Bancel | 21,307,198 |
5.36% | Flagship Pioneering | 17,281,016 |
4.34% | SSgA Funds Management, Inc. | 14,847,130 |
3.73% | Robert Langer | 11,510,060 |
2.89% | BlackRock Fund Advisors | 7,472,252 |
1.88% | Coatue Management LLC | 6,928,147 |
1.74% | Geode Capital Management LLC | 6,436,354 |
1.62% | Thélème Partners LLP | 6,336,940 |
1.59% |
|
|
|
- Nasdaq Global Select Market - Nasdaq 100 / S&P 500, Stoxx Americas 100 |
|
|
|
- Bloomberg Code : |
|
- Reuters Code : |
MRNA.O |
- Datastream Code : |
|
|
Company contact information |
|
|
|
|
|
COVID-19 vaccine scheme for world's poorest pushes for delivery slowdown |
Sector Other Biotechnology & Medical Research
Connections : Moderna, Inc.
|